A 12-year study led by a team of University of Arizona Cancer Center researchers is bringing into question the safety and efficacy of selenium, a popular nutritional supplement touted to combat and reduce the risk of colorectal cancer.
The findings indicate the need for a significant change in practice, given that selenium supplements cannot be recommended for preventing colorectal cancer.
Selenium has been a popular nutritional supplement for decades, touted for its antioxidant properties and its role in stopping free radicals from damaging cells and DNA. Studies have shown a deficiency of this micronutrient to be associated with cancer risk.
However, a randomized clinical trial involving 1,824 participants from clinical centers in Arizona, Colorado, Texas and New York indicates that selenium supplements failed to prevent the development of colon polyps, but significantly increased the risk of developing type 2 diabetes in older individuals.
“The possibility that selenium supplements may increase the risk of type 2 diabetes has been hinted at before,” said Peter Lance, MD, deputy director of the UA Cancer Center and the study’s principal investigator. “But this is the first study to have substantiated such a risk in the setting of a prospective, randomized, placebo-controlled trial.” Study participants were randomized to take 200 mcg of selenium as selenized yeast or a placebo daily.
The trial also looked at celecoxib, a selective COX-2 inhibitor non-steroidal anti-inflammatory drug (NSAID), versus placebo. While the once-daily 400 mg dose prevented colon polyps in high-risk patients, it increased the risk of hypertension in those with pre-existing cardiovascular risk factors. “Our study has added important refinements to understanding who may benefit most from the colon polyp-preventing effects of celecoxib and how best to avoid cardiovascular toxicity caused by this agent,” added Dr. Lance.
Further UA-led studies are under way to define the biological mechanisms underlying the effects, including toxicity, of selenium supplements. A study is planned to target celecoxib to those patients who will benefit most from the colon polyp-preventing actions of celecoxib while minimizing cardiovascular toxicity.
The findings of the Selenium and Celecoxib Trial recently were published online before print in two articles in the Journal of the National Cancer Institute (JNCI): “Selenium Supplementation for Prevention of Colorectal Adenomas and Risk of Associated Type 2 Diabetes” and “Celecoxib for the Prevention of Colorectal Adenomas: Results of a Suspended Randomized Controlled Trial.” The articles will appear in print in the December 2016 issue of JNCI.
In addition to Dr. Lance, other members of the study’s research team were UA Cancer Center members Patricia A. Thompson (now with the State University of New York at Stony Brook), Erin L. Ashbeck, Denise J. Roe, Liane Fales, Julie Buckmeier, Fang Wang, Achyut Bhattacharyya, Chiu-Hsieh Hsu, H-H. Sherry Chow, David S. Alberts and Elizabeth T. Jacobs; and also Dennis J. Ahnen, Denver Department of Veterans Affairs Medical Center and University of Colorado; C. Richard Boland, Baylor University Medical Center; Russell I. Heigh, Mayo Clinic, Scottsdale; David E. Fay, Endoscopy Center of Western New York; Stanley R. Hamilton, The University of Texas MD Anderson Cancer Center; and Maria Elena Martinez, University of California, San Diego.
The Selenium and Celecoxib Trial was supported by National Cancer Institute grants P01 CA041108 and R01 CA151708.
About the University of Arizona Cancer Center
The University of Arizona Cancer Center is the only National Cancer Institute-designated Comprehensive Cancer Center headquartered in Arizona. The UA Cancer Center is supported by NCI Cancer Center Support Grant number P30CA023074. With primary locations at the University of Arizona in Tucson and at Dignity Health St. Joseph’s Hospital and Medical Center in Phoenix, the UA Cancer Center has more than a dozen research and education offices in Phoenix and throughout the state and 300 physician and scientist members working together to prevent and cure cancer. For more information, please go to uacc.arizona.edu
About the UA Health Sciences
The University of Arizona Health Sciences is the statewide leader in biomedical research and health professions training. The UA Health Sciences includes the UA Colleges of Medicine (Phoenix and Tucson), Nursing, Pharmacy and Mel and Enid Zuckerman College of Public Health, with main campus locations in Tucson and the growing Phoenix Biomedical Campus in downtown Phoenix. From these vantage points, the UA Health Sciences reaches across the state of Arizona and the greater Southwest to provide cutting-edge health education, research, patient care and community outreach services. A major economic engine, the UA Health Sciences employs almost 5,000 people, has nearly 1,000 faculty members and garners more than $126 million in research grants and contracts annually. For more information: http://uahs.arizona.edu